<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4050">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03054194</url>
  </required_header>
  <id_info>
    <org_study_id>E2730-A001-001</org_study_id>
    <nct_id>NCT03054194</nct_id>
  </id_info>
  <brief_title>Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2730</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2730</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study E2730-A001-001 is a first-in-human, sequential ascending single dose,
      placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics (PK) of
      a single oral dose of E2730 in healthy participants.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with any serious adverse event and number of participants with any non-serious adverse event</measure>
    <time_frame>up to Day 10 (Follow-up/Early Termination)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with an abnormal, clinically significant hematology parameter value</measure>
    <time_frame>Screening; Baseline; Days 2 and 5; Day 10 (Follow-up/Early Termination)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with an abnormal, clinically significant blood chemistry parameter value</measure>
    <time_frame>Screening; Baseline; Days 2 and 5; Day 10 (Follow-up/Early Termination)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with an abnormal, clinically significant urine value</measure>
    <time_frame>Screening; Baseline; Days 2 and 5; Day 10 (Follow-up/Early Termination)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with an abnormal, clinically significant vital sign value</measure>
    <time_frame>up to Day 10 (Follow-up/Early Termination)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from Baseline in weight</measure>
    <time_frame>Screening; Baseline; Day 10 (Follow-up/Early Termination)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with an abnormal, clinically significant electrocardiogram (ECG) parameter value</measure>
    <time_frame>Screening; Baseline; up to Day 10 (Follow-up/Early Termination)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with an abnormal, clinically significant physical examination parameter value</measure>
    <time_frame>Screening; Baseline; Day 5; Day 10 (Follow-up/Early Termination)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with an abnormal, clinically significant neurological parameter value</measure>
    <time_frame>Screening</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean maximum observed concentration (Cmax) for E2730 and the N-acetyl metabolite in plasma</measure>
    <time_frame>Day 1: predose; 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 18 hours postdose. 24 (Day 2), 36 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 216 hours (Day 10) postdose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean time at which the highest drug concentration (tmax) occurs for E2730 and the N-acetyl metabolite in plasma</measure>
    <time_frame>Day 1: predose; 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 18 hours postdose. 24 (Day 2), 36 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 216 hours (Day 10) postdose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean area under the concentration-time curve from zero time to 24 hours after dosing (AUC[0-24h]) for E2730 and the N-acetyl metabolite in plasma</measure>
    <time_frame>Day 1: predose; 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 18 hours postdose. 24 (Day 2), 36 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 216 hours (Day 10) postdose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean area under the concentration-time curve from zero time to time of last quantifiable concentration (AUC[0-t]) for E2730 and the N-acetyl metabolite in plasma</measure>
    <time_frame>Day 1: predose; 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 18 hours postdose. 24 (Day 2), 36 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 216 hours (Day 10) postdose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean area under the concentration-time curve from zero time to 72 hours after dosing (AUC[0-72h]) for E2730 and the N-acetyl metabolite in plasma</measure>
    <time_frame>Day 1: predose; 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 18 hours postdose. 24 (Day 2), 36 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 216 hours (Day 10) postdose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean area under the concentration-time curve from zero time to 96 hours after dosing (AUC[0-96h]) for E2730 and the N-acetyl metabolite in plasma</measure>
    <time_frame>Day 1: predose; 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 18 hours postdose. 24 (Day 2), 36 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 216 hours (Day 10) postdose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean area under the concentration-time curve from zero time extrapolated to infinite time (AUC[0-inf]) for E2730 and the N-acetyl metabolite in plasma</measure>
    <time_frame>Day 1: predose; 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 18 hours postdose. 24 (Day 2), 36 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 216 hours (Day 10) postdose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean terminal phase half-life (t1/2) for E2730 and the N-acetyl metabolite in plasma</measure>
    <time_frame>Day 1: predose; 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 18 hours postdose. 24 (Day 2), 36 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 216 hours (Day 10) postdose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean apparent total clearance following extravascular (eg, oral) administration of E2730 (CL/F) in plasma</measure>
    <time_frame>Day 1: predose; 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 18 hours postdose. 24 (Day 2), 36 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 216 hours (Day 10) postdose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean apparent volume of distribution at terminal phase (Vz/F) for E2730 in plasma</measure>
    <time_frame>Day 1: predose; 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 18 hours postdose. 24 (Day 2), 36 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 216 hours (Day 10) postdose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolite ratio (%) calculated as the ratio of plasma AUC(0-inf) of metabolite to parent following molar correction (MRP) for E2730 and the N-acetyl metabolite</measure>
    <time_frame>Day 1: predose; 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 18 hours postdose. 24 (Day 2), 36 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 216 hours (Day 10) postdose.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline in blood pressure (BP) using ambulatory BP monitoring (ABPM)</measure>
    <time_frame>Baseline; Day 1; Day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline in heart rate using Holter monitoring</measure>
    <time_frame>Baseline; Day 1; Day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline in corrected QT (QTc) interval using Holter monitoring</measure>
    <time_frame>Baseline; Day 1; Day 2</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Dose 1 E2730</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Dose 1 of oral E2730 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1: Matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive matching oral placebo on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Dose 2 E2730</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Dose 2 of oral E2730 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive oral matching placebo on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Dose 3 E2730</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Dose 3 of oral E2730 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive oral matching placebo on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2730</intervention_name>
    <description>capsules</description>
    <arm_group_label>Cohort 1: Dose 1 E2730</arm_group_label>
    <arm_group_label>Cohort 2: Dose 2 E2730</arm_group_label>
    <arm_group_label>Cohort 3: Dose 3 E2730</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>capsules</description>
    <arm_group_label>Cohort 1: Matching placebo</arm_group_label>
    <arm_group_label>Cohort 2: Matching placebo</arm_group_label>
    <arm_group_label>Cohort 3: Matching placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-smoking, male or female, age ≥18 years and ≤55 years old at the time of informed
             consent (note: to be considered non-smokers, participants must have discontinued
             smoking for at least 4 weeks before dosing)

          -  Body mass index (BMI) ≥18 and &lt;32 kilograms per meters squared (kg/m^2) at Screening

        Exclusion Criteria:

          -  Clinically significant illness that requires medical treatment within 8 weeks or a
             clinically significant infection that requires medical treatment within 4 weeks of
             dosing

          -  Females who are breastfeeding or pregnant at Screening or Baseline (documented by a
             negative beta human chorionic gonadotropin [β-hCG] (or human chorionic gonadotropin
             [hCG]) test with a minimum sensitivity of 25 International Units per Liter [IU/L] or
             equivalent units of β-hCG [or hCG]). A negative urine pregnancy test is required
             before the administration of the first dose per cohort.

          -  Females of childbearing potential who:

               -  Had unprotected sexual intercourse within 30 days before study entry and do not
                  agree to use a highly effective method of contraception (eg, total abstinence,
                  an intrauterine device, a double barrier method [such as condom plus diaphragm
                  with spermicide] or have a vasectomized partner with confirmed azoospermia but
                  hormonal contraceptives are not permitted) throughout the entire study period
                  and for 28 days after study drug discontinuation

               -  Are currently abstinent, and do not agree to use a double barrier method (as
                  described above) or refrain from sexual activity during the study period or for
                  28 days after study drug discontinuation

        NOTE: All females will be considered to be of childbearing potential unless they are
        postmenopausal (amenorrheic for at least 12 consecutive months, in the appropriate age
        group, and without other known or suspected cause) or have been sterilized surgically (ie,
        bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery
        at least 1 month before dosing).

          -  Males who have not had a successful vasectomy (confirmed azoospermia) or they and
             their female partners do not meet the criteria above (ie, not of childbearing
             potential or practicing highly effective contraception throughout the study period or
             for 28 days after study drug discontinuation). No sperm donation is allowed during
             the study period or for 3 months after study drug discontinuation.

          -  Evidence of disease that may influence the outcome of the study within 4 weeks before
             dosing (eg, psychiatric disorders and disorders of the gastrointestinal tract, liver,
             kidney, respiratory system, endocrine system, hematological system, neurological
             system, or cardiovascular system, or participants who have a congenital abnormality
             in metabolism)

          -  Any history of seizures, including those experienced in childhood

          -  Any history of gastrointestinal surgery that may affect pharmacokinetic profiles of
             E2730 (eg, hepatectomy, nephrectomy, digestive organ resection) at Screening

          -  Any clinically abnormal symptom or organ impairment found by medical history,
             physical examinations, vital signs, electrocardiogram (ECG) finding, or laboratory
             test results that require medical treatment at Screening or Baseline

          -  A prolonged QT/QT corrected (QTc) interval (QC interval corrected using Fridericia's
             formula [QTcF] &gt;450 milliseconds) demonstrated on ECG at Screening or Baseline (based
             on average of triplicate ECGs). A history of risk factors for torsade de pointes (eg,
             heart failure, hypokalemia, family history of long QT Syndrome) or the use of
             concomitant medications that prolonged the QT/QTc interval

          -  Left bundle branch block at Screening or Baseline

          -  Persistent systolic blood pressure (BP) &gt;130 or &lt;100 millimeters of mercury (mmHg) or
             diastolic BP &gt;85 or &lt;50 mmHg at Screening or Baseline

          -  Persistent heart rate less than 50 beats/min or more than 100 beats/min at Screening
             or Baseline

          -  History of myocardial infarction, ischemic heart disease, or cardiac failure at
             Screening

          -  History of clinically significant arrhythmia or uncontrolled arrhythmia

          -  Known history of clinically significant drug allergy at Screening or Baseline

          -  Known history of food allergies or presently experiencing significant seasonal or
             perennial allergy at Screening or Baseline

          -  Known to be human immunodeficiency virus positive at Screening

          -  Active viral hepatitis (A, B, or C) as demonstrated by positive serology at Screening

          -  History of drug or alcohol dependency or abuse within the 2 years before Screening,
             or those who have a positive drug test (including cannabinoids) or alcohol test at
             Screening or Baseline

          -  Intake of caffeinated beverages or food within 72 hours before dosing

          -  Intake of nutritional supplements, juice, and herbal preparations or other foods or
             beverages that may affect the various drug-metabolizing enzymes and transporters (eg,
             alcohol, grapefruit, grapefruit juice, grapefruit-containing beverages, apple or
             orange juice, vegetables from the mustard green family [eg, kale, broccoli,
             watercress, collard greens, kohlrabi, Brussel's sprouts, mustard], and charbroiled
             meats) within 1 week before dosing

          -  Intake of herbal preparations containing St. John's Wort within 4 weeks before dosing

          -  Use of prescription drugs within 4 weeks before dosing

          -  Intake of over-the-counter (OTC) medications within 2 weeks before dosing

          -  Currently enrolled in another clinical study or used any investigational drug or
             device within 30 days or 5 half-lives, whichever is longer, preceding informed
             consent

          -  Receipt of blood products within 4 weeks, or donation of blood within 8 weeks, or
             donation of plasma within 1 week of dosing

          -  Engagement in strenuous exercise within 2 weeks before check-in (eg, marathon
             runners, weight lifters)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eisai Medical Information</last_name>
    <phone>1-888-422-4743</phone>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 13, 2017</lastchanged_date>
  <firstreceived_date>February 13, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy participants</keyword>
  <keyword>E2730</keyword>
  <keyword>Pharmacokinetics</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
